- Dementia drugs hailed as 'beginning of the end' for Alzheimer's do not work, major report finds Daily Mail —
- 'Breakthrough' Alzheimer's drugs unlikely to benefit patients, report suggests BBC News —
- Much-hyped Alzheimer’s drugs do not help patients, review finds The Straits Times —
- Alzheimer’s drugs ‘make no meaningful difference to patients,’ major review suggests The Independent —
- Alzheimer's drugs make 'no meaningful difference' RTE —
- Alzheimer’s drugs targeting amyloid don’t help, review finds The Japan Times —
- Effect of ‘gamechanger’ Alzheimer’s drugs ‘trivial’, review concludes The Guardian —
- Analysis of Alzheimer’s Drugs Stirs Debate About Their Effectiveness The New York Times —
- Alzheimer’s drugs ‘make no meaningful difference to patients’, say researchers Belfast Telegraph —
- Alzheimer’s bombshell as top scientists conclude - ‘the drugs don’t work’ Mirror —
- Alzheimer’s drugs ‘make no meaningful difference to patients’, say researchers The Standard —
- Alzheimer's 'wonder drugs' do not work, major study finds despite hopes of end to disease LBC —
- New Alzheimer’s drugs make ‘no meaningful difference’ to patients The Times —
- What’s the deal with Alzheimer’s disease and amyloid? Ars Technica —
Donanemab
Experimental drug for the treatment of Alzheimer's disease
Donanemab, sold under the brand name Kisunla, is a monoclonal antibody used for the treatment of Alzheimer's disease. Donanemab was developed by Eli Lilly and Company.
Also known as...
LY3002813
Alzheimer's Drugs Benefits Labeled 'Trivial'